89bio Statistics

Total Valuation

89bio has a market cap or net worth of $821.51 million. The enterprise value is $286.52 million.

Market Cap	821.51M
Enterprise Value	286.52M

Important Dates

The next estimated earnings date is Wednesday, August 7, 2024, after market close.

Earnings Date	Aug 7, 2024
Ex-Dividend Date	n/a

Share Statistics

89bio has 98.38 million shares outstanding. The number of shares has increased by 80.26% in one year.

Shares Outstanding	98.38M
Shares Change (YoY)	+80.26%
Shares Change (QoQ)	+18.62%
Owned by Insiders (%)	0.71%
Owned by Institutions (%)	107.34%
Float	69.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.61
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.03, with a Debt / Equity ratio of 0.05.

Current Ratio	15.03
Quick Ratio	n/a
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-43.97

Financial Efficiency

Return on equity (ROE) is -34.80% and return on invested capital (ROIC) is -33.46%.

Return on Equity (ROE)	-34.80%
Return on Assets (ROA)	-31.00%
Return on Capital (ROIC)	-33.46%
Revenue Per Employee	n/a
Profits Per Employee	-$2.36M
Employee Count	70
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, 89bio has paid $3.96 million in taxes.

Income Tax	3.96M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -52.98% in the last 52 weeks. The beta is 1.00, so 89bio's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	-52.98%
50-Day Moving Average	8.41
200-Day Moving Average	9.59
Relative Strength Index (RSI)	49.40
Average Volume (20 Days)	1,332,774

Short Selling Information

The latest short interest is 6.42 million, so 6.53% of the outstanding shares have been sold short.

Short Interest	6.42M
Short Previous Month	9.02M
Short % of Shares Out	6.53%
Short % of Float	9.20%
Short Ratio (days to cover)	4.56

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-179.96M
Pretax Income	-161.07M
Net Income	-165.03M
EBITDA	-157.09M
EBIT	-157.49M
Earnings Per Share (EPS)	-$2.01

Full Income Statement

Balance Sheet

The company has $562.29 million in cash and $27.30 million in debt, giving a net cash position of $534.99 million or $5.44 per share.

Cash & Cash Equivalents	562.29M
Total Debt	27.30M
Net Cash	534.99M
Net Cash Per Share	$5.44
Equity (Book Value)	510.54M
Book Value Per Share	5.19
Working Capital	536.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$138.82 million and capital expenditures -$4,000, giving a free cash flow of -$138.83 million.

Operating Cash Flow	-138.82M
Capital Expenditures	-4,000
Free Cash Flow	-138.83M
FCF Per Share	-$1.45

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

89bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-80.26%
Shareholder Yield	-80.26%
Earnings Yield	-20.09%
FCF Yield	-16.90%

Dividend Details

Analyst Forecast

The average price target for 89bio is $26.67, which is 219.40% higher than the current price. The consensus rating is "Buy".

Price Target	$26.67
Price Target Difference	219.40%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-13.04%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1